Therapeutic effect and lymphocyte subsets of combination therapy with Carolizumab and Anlotinib in advanced esophageal cancer patients
Objective To observe and analyze the clinical efficacy and impact on lymphocyte subsets of patients with advanced esophageal cancer treated with a combination of Carolizumab and Anlotinib.Methods A totol of 116 patients with advanced esophageal cancer who underwent treatment from January 2020 to March 2023 were divided into two groups,both using the TP regimen.The random number table method was used as the grouping tool.The control group was treated with a combination of Carrelizumab injection,while the observation group was treated with a combination of Carrelizumab and Anlotinib.The recent clinical efficacy,prognosis,and postoperative complications were compared.Results Compared with the control group,the objective remission rate,and the total clinical efficacy rate in the observation group were much higher(P＜0.05).There was no significant difference in CD4+,CD8+,CD4+/CD8+,and NK cell levels between the two groups before treatment(P＞0.05).After treatment,the CD4+,CD4+/CD8+,and NK cell levels in the observation group were much higher,while CD8+was lower than those in the control group(P＜0.05).Before treatment,there was no significant difference in the levels of squamous cell carcinoma-related antigen(SCC-Ag),high mobility group box 1(HMGB1),and carcinoma embryonic antigen(CEA)between the two groups(P＞0.05).After treatment,the levels of various serum tumor markers in the observation group were much lower(P＜0.05).The observation group had higher rates of grade Ⅲ hoarseness,grade Ⅲ pneumonia,and grade Ⅲ pneumothorax compared to the control group(P＜0.05).Conclusion The combined use of Karelizumab and Anlotinib in advanced esophageal cancer patients can significantly improve short-term clinical efficacy,reduce serum tumor marker levels,and effectively alleviate the impact on immunity.
万方数据
维普
